期刊
EMBO MOLECULAR MEDICINE
卷 13, 期 2, 页码 -出版社
WILEY
DOI: 10.15252/emmm.202012640
关键词
EC8042; epigenetics; mithramycin; pediatric cancer; SWI; SNF
资金
- National Cancer Institute of the National Institutes of Health [F31-CA236300-01]
- Van Andel Research Institute
- Children's Hospital of Philadelphia
- Alex's Lemonade Stand Foundation
The study found that rhabdoid tumors are more sensitive to mithramycin and EC8042, with their sensitivity superior to traditional DNA damaging agents and linked to the causative mutation of SMARCB1 deletion in the tumor. Mithramycin can block the activity of SMARCB1-deficient SWI/SNF complex, leading to chromatin remodeling and restoration of cellular differentiation.
Rhabdoid tumor (RT) is a pediatric cancer characterized by the inactivation of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. Although this deletion is the known oncogenic driver, there are limited effective therapeutic options for these patients. Here we use unbiased screening of cell line panels to identify a heightened sensitivity of rhabdoid tumor to mithramycin and the second-generation analogue EC8042. The sensitivity of MMA and EC8042 was superior to traditional DNA damaging agents and linked to the causative mutation of the tumor, SMARCB1 deletion. Mithramycin blocks SMARCB1-deficient SWI/SNF activity and displaces the complex from chromatin to cause an increase in H3K27me3. This triggers chromatin remodeling and enrichment of H3K27ac at chromHMM-defined promoters to restore cellular differentiation. These effects occurred at concentrations not associated with DNA damage and were not due to global chromatin remodeling or widespread gene expression changes. Importantly, a single 3-day infusion of EC8042 caused dramatic regressions of RT xenografts, recapitulated the increase in H3K27me3, and cellular differentiation described in vitro to completely cure three out of eight mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据